Meeting
2022 ASCO Genitourinary Cancers Symposium
TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.
Authors
Christof Vulsteke
Integrated Cancer Center in Ghent, Maria Middelares, and Center for Oncological Research (CORE), University of Antwerp, Ghent, Belgium
Christof Vulsteke , Petros Grivas , Scott T. Tagawa , Joaquim Bellmunt , Maria De Santis , Ignacio Duran , Peter-Juergen Goebell , Andrea Necchi , Srikala S. Sridhar , Cora N. Sternberg , Mitchell Robert Sierecki , Usman Aziz , Trishna Goswami , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04527991
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS582)
DOI
10.1200/JCO.2022.40.6_suppl.TPS582
Abstract #
TPS582
Poster Bd #
M2
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.
First Author: Petros Grivas
Poster
2023 ASCO Annual Meeting
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Yohann Loriot
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Scott T. Tagawa
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak